MAMarko Andabaka

Marko Andabaka

*This is an algorithmically generated author record based on publicly available information.

Marko Andabaka has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Significance of molecular biomarkers in the diagnosis of neuromyelitis optica spectrum disorder

    by Marko Andabaka, Jelena Drulović, Ivana Novaković

    Discovery of antibodies to aquaporin-4 channels as a laboratory or molecular biomarker for neuromyelitis optica spectrum disorder contributed to a better understanding of the etiopathogenesis, with a clear separation of the clinical, neuroradiological and laboratory characteristics of this disease. This resulted in the definition of criteria for establishing the diagnosis of neuromyelitis optica spectrum disorder and a clear distinction in relation to multiple sclerosis. Clinical presentation of the inflammatory diseases of the central nervous system may be highly variable, with numerous, often overlapping symptoms and signs. Therefore, in the differential diagnostic, in addition to the clinical presentation, it is necessary to consider paraclinical characteristics, such as laboratory findings of the blood and cerebrospinal fluid and the neuroradiological examination findings. Since aquaporin-4 is a clearly defined, crucial diagnostic biomarker in the neuromyelitis optica spectrum disorder, different methodological approaches were developed to evaluate antibodies to aquaporin-4, taking into account the specificity and sensitivity of the tests themselves. One of the first tests that was routinely applied in clinical practice for the detection of antibodies to aquaporin-4, were tests in the form of an immunoenzymatic assay that showed great variability in the degree of specificity and sensitivity. The second group of tests for the detection of antibodies to aquaporin-4 applied the technique of indirect immunofluorescence on a substrate of animal origin, which achieved a higher degree of sensitivity and specificity, with certain disadvantages, such as the impossibility of precise quantification as well as difficulties in the interpretation of the results. Special methodological principles of immunoprecipitation such as fluorescent and radioimmunoprecipitation did not achieve a satisfactory level of sensitivity in the detection of antibodies to aquaporin-4. The highest level of sensitivity with absolute specificity has been achieved via developing a cell assay methodology, based on the application of human aquaporin-4 transfected cells fixed on a biochip, with a negative control when antibodies to aquaporin-4 from serum are detected by indirect immunofluorescence methodology or special cellular assays, and when these antibodies are quantified by flow cytometry method. Using this cell assay methodology is extremely important in order to establish the correct diagnosis of seropositive neuromyelitis optica spectrum disorder.

  • Open Access

    Neuromyelitis Optica spectrum disorders: Therapeutic considerations

    by Marko Andabaka, Šarlota Mesaroš, Nikola Veselinović, Olivera Tamaš, Maja Budimkić, Jelena Drulović

    Neuromyelitis Optica spectrum disorder (NMOSD) is a rare but debilitating autoimmune disease of the central nervous system (CNS) for which several biological therapies have been approved recently. Historically, NMOSD disease-modifying treatments relied on wide-spectrum off-label conventioanl immunosuppressants, such as azathioprine, and mycophenolate mofetil. Since 2015, evidence has accumulated to support off-label biological therapy (rituximab) and to approve satralizumab, inebilizumab, eculizumab, and ravulizumab. This next generation of drugs provides several targeted disease-modifying treatment options for NMOSD. Here, we first review the mechanistic rationales associated with their specific targets. Then we review the pivotal evidence supporting their use in practice. The current therapeutic options in NMOSD comprise three targeted mechanisms at different stages of a unique tissue-injury cascade: B-cell depleting, anti-cytokine, and anti-complement therapies. One drug from each class has been approved for market release. The current consensus proposes positioning the approved drugs as first-line treatments for newly diagnosed patients and as alternative therapies in case of failure of historical treatment.